To investigate the heterogeneity of clinically meaningful levels of gait speed relative to selfreported mobility disability (SR-MD). DESIGN: Five longitudinal studies with older adults in different health states (onset of acute event, presence of chronic condition, sedentary, community living) were used to explore the relationship between gait speed and SR-MD. Key words: mobility disability; usual-pace 3-to 4-m gait speed; stair climb G ait speed is associated with a multitude of health outcomes in older adults. [1] [2] [3] [4] [5] [6] Consensus groups focusing on definitions of sarcopenia that integrate physical function have recommended gait speeds slower than 1.0 m/s 7 and slower than 0.8 m/s 8 for identifying persons at risk of disability, hospitalization, and death. Changes in gait speed of 0.04 to 0.06 m/s are associated with small to medium, clinically meaningful changes in mobility limitations and disability. 9, 10 Particularly relevant to the current From the
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ait speed is associated with a multitude of health outcomes in older adults. [1] [2] [3] [4] [5] [6] Consensus groups focusing on definitions of sarcopenia that integrate physical function have recommended gait speeds slower than 1.0 m/s 7 and slower than 0.8 m/s 8 for identifying persons at risk of disability, hospitalization, and death. Changes in gait speed of 0.04 to 0.06 m/s are associated with small to medium, clinically meaningful changes in mobility limitations and disability. 9, 10 Particularly relevant to the current investigation, one study 11 concluded that estimates of small and substantial declines in mobility measured according to gait speed were generally consistent in a variety of subgroups (e.g., sex, body mass index, chronic conditions).
There is evidence that lower extremity performance measures can be incorporated into annual provider visits. 12 This necessitates a greater understanding of the clinical relevance of gait speed relative to important cutpoints and changes in different populations. For example, it was 13 recently suggested that a very slow gait speed (0.6 m/s) may be used to develop a definition for a diagnosis of dysmobility in clinical care settings. With this in mind, we explored the potential heterogeneity of the relationships between gait speed and self-reported mobility disability (SR-MD) from 5 studies of older adults ( 65) in different health states (onset of acute event, presence of chronic condition, sedentary, community living). We focused on whether gait speed measured over 3 or 4 m has similar predictive characteristics for concurrently measured SR-MD and, within these studies, whether optimally estimated gait speed cutpoints for SR-MD are similar in different populations. We also investigated the longitudinal relationship between changes in gait speed and development of (recovery from) SR-MD. Differences according to sex are explored within all analyses where possible.
METHODS

Included Studies
We included data from participants aged 65 and older at entry that were randomized in three studies in which SR-MD and gait speed were measured concurrently: The Lifestyle Interventions and Independence for Elders Pilot (LIFE-P) and main studies (LIFE) and the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN). Briefly, LIFE-P/LIFE included community-dwelling persons who, at baseline, were able to walk 400 m within 15 minutes, scored less than 10 on the Short Physical Performance Battery, and were sedentary but without comorbidity that precluded full participation in a physical activity intervention. TRAIN participants had high cardiovascular risk. The Invecchiare in Chianti (InCHIANTI) Study provided a community-based sample of older adults in Italy, and the Baltimore Hip Study (BHS2) was selected to provide a sample of older adults who had been suddenly disabled after hip fracture. Details on the design and inclusion criteria for each of the included studies 2,14-17 have been previously published and are briefly summarized in Supplemental Table S1 .
Disability Measurements
Consistent with the literature, 18, 19 we defined SR-MD as inability to walk 1 block or climb 1 flight of stairs. Information on SR-MD was collected using the same questions in LIFE-P, LIFE, and TRAIN, and SR-MD was defined as any response of "unable to do" or "usually did with a lot of difficulty" to separate questions about walking 1 block or climbing 1 flight of stairs: "How hard was it to do the activity because of your health?" during the past month, by yourself. In BHS2, SR-MD was defined by combining questions about the need for human or equipment assistance and difficulty walking 1 block and climbing 5 stairs over the past week, collected 2, 6, and 12 months after fracture. SR-MD was defined as receiving human assistance to perform the activity, inability to perform the activity for health reasons, or indicating that performing the activity was extremely difficult. For InCHIANTI, we selected 2 questions that resembled the questions used in the other studies: "How much difficulty do you have walking 100 meters?" and "Can you walk up a flight of 12 to 15 steps?" SR-MD was defined as "incapable" of or "a lot of difficulty" in walking 100 m or a response of "no" to walking up a flight of 12 to 15 steps. As a reference, city blocks in several major U.S. cities range from 80 to 120 m long.
Gait Speed Measurements
Gait speed was obtained from a 3-or 4-m walk test. Participants were asked to walk at their normal pace, and speed was calculated as distance in meters divided by time in seconds.
Statistical Analyses
Descriptive statistics for age, sex, race, and body mass index were summarized by study using means with standard deviations and proportions. LIFE and LIFE-P data are presented as a single study because inclusion and exclusion criteria were the same.
Cross-Sectional Analyses
Cross-sectional analyses were performed using data from all visits at which information on gait speed and both components of SR-MD (walking, stair climb) was available. To account for multiple visits per person, generalized estimating equations (GEEs) were used to perform studyspecific logistic regression predicting the presence of SR-MD as a function of gait speed collected at the same time. Estimation was performed under working independence (i.e., using Independence Estimating Equations) and exchangeable covariance assumptions and hypothesis testing used a robust covariance, but because results were similar using both approaches, only Independence Estimating Equation results are presented in the text and tables. (See Supplemental Table S2 for a comparison of results.) Area under the receiver operating characteristic (ROC) curve (AUC) and 95% confidence intervals (CIs) 20 were obtained for each model. An optimal gait speed cutpoint (and associated predicted probability from logistic regression) was chosen using the maximum Youden distance criteria, which gives equal weight to sensitivity and specificity in selecting a statistically optimal cutpoint. Bootstrapped 95% CIs were calculated for this cutpoint. For each study, predicted probabilities were obtained and plotted against gait speed. Main effects for sex and interactions between sex and gait speed were evaluated, setting statistical significance at the .05 Type I error level.
Longitudinal Analyses
TRAIN had few participants transitioning between the absence and presence of SR-MD at successive visits; thus, only BHS2, InCHIANTI, and LIFE-P/LIFE studies were included in longitudinal analyses of successive visits. InCHIANTI (34 intervals) had insufficient intervals with participants transitioning out of SR-MD to permit modelling of the recovery transition. Where visits were missed, we excluded some longer, nonstandard time intervals so as to standardize the time frames within study. (See details in Supplemental Table S1 footnotes.) The length of time between visits was also considered in the modelling approach.
As in the cross-sectional analyses, GEEs were used to perform study-specific logistic regression with separate models predicting the development of, or recovery from, SR-MD as a function of gait speed measured at the initial visit and change in gait speed during follow-up. Initially, a model was fit containing initial gait speed measure, change in gait speed, and the interaction between the initial measure and change, controlling for time between visits. If the interaction was not statistically significant at the nominal .05 level, it was dropped. Subsequently, we explored whether an interaction between change in gait speed and elapsed time between measurements was needed. Finally, we determined whether a main effect for time between measurements was needed in each study. For each model, the AUC was obtained, and predicted probabilities were plotted against change in gait speed for various initial levels of gait speed. Because absence of an interaction between initial speed and change in speed on the multiplicative (logit) scale does not denote absence on the additive scale, 21, 22 we performed contrasts (and bootstrapped 95% CIs) for additive interactions based on selected gait speeds. Finally, for InCHIANTI and LIFE-P/LIFE, interactions between sex, and both initial gait speed, and change in gait speed were evaluated, setting statistical significance at the .05 Type I error level. BHS2 had too few reports of SR-MD (n56) in men to explore such interactions. Table 1 provides descriptive statistics according to study. Age in our samples ranged from 65 to 102, and the majority of participants were women, with the exception of TRAIN (39% women). The proportion of participants who were white ranged from a low of 76% in LIFE-P/ LIFE to 100% in InCHIANTI. The percentage of visits at which mobility disability was reported ranged from 5.4% in TRAIN to 40.7% in BHS2.
RESULTS
Cross-Sectional Results
Descriptive statistics and cross-sectional logistic regression results are presented at the bottom of Table 1 . The mean gait speed of participants without SR-MD was greater than 1.0 m/s in InCHIANTI and TRAIN, 0.79 m/s in LIFE-P/LIFE, and 0.46 m/s in BHS2. Mean gait speed of participants with SR-MD ranged from 0.08 m/s slower in LIFE-P/LIFE to as much as 0.36 m/s slower in InCHIANTI. Logistic regression identified that the linear gait speed term was a significant predictor of SR-MD (p<.01) in all studies. The smallest AUC was 0.69 (LIFE-P/LIFE) and the largest was 0.92 (InCHIANTI). The optimal gait speed cutpoint for minimizing misclassification of SR-MD ranged from 0.3 m/s in BHS2 to 1.0 m/s in TRAIN. The predicted probability of SR-MD estimated at these cutpoints ranged from a low probability of 0.07 in TRAIN to a high of 0.45 in BHS2 (Figure 1) . The difference in predicted probability of SR-MD between those with gait speed of 0.5 m/s and 0.7 m/s in BHS2 (probability of 0.16 at 0.5 m/s vs 0.04 at 0.7 m/s; difference50.12 m/s) is half the difference observed for InCHIANTI (probability of 0.35 at 0.5 m/s vs 0.11 at 0.7 m/s; difference50.24 m/s) but similar to that for LIFE-P/LIFE (probability of 0.21 at 0.5 m/s vs 0.10 at 0.7 m/s; difference50.11 m/s). Within studies, no appreciable sex differences in predicted probabilities for selected gait speeds were apparent (Supplemental Figure S1 ).
Longitudinal Results
Descriptive statistics for gait speed according to study and type of longitudinal transition in SR-MD are presented in Table 2 . For participants who reported no SR-MD at a prior visit, SR-MD was reported at the subsequent visit 11.8% (n523) of the time in BHS2, 4.4% (n560) in InCHIANTI, and 5.9% (n5368) in LIFE-P/LIFE. An additional decline of 0.06 m/s (95% CI50.04-0.08 m/s) in gait speed was observed in LIFE-P/LIFE in those who transitioned to SR-MD versus those who did not transition, 0.1 m/s (95% CI50.02-0.17 m/s) in BHS2, and 0.24 m/s (95% CI50.17-0.30 m/s) in InCHIANTI.
For participants who reported SR-MD at a prior visit, no SR-MD was reported at the subsequent visit 41.6% (N552) of the time in BHS2 and 53.4% (N5267) in LIFE-P/LIFE. In comparison to participants that reported SR-MD at the subsequent visit, mean change in gait speed among those without subsequent SR-MD was 0.13 m/s (95% CI 0.05-0.21 m/s) larger in BHS2 and 0.04 m/s (95% CI 0.02-0.06 m/s) larger in LIFE-P/LIFE.
Logistic regression identified significant effects (p<.001, Table 2, Figure 2A ) of the initial gait speed and change in gait speed on the development of SR-MD in all studies. (See Supplemental Table 3 for a comparison of results under exchangeable and independence correlation assumptions) Neither the time interval effect nor the interaction terms between initial speed and change in speed were significant on the multiplicative scale, but contrasts for interaction on the additive scale (Table 3) at selected speeds identified that the effect of change in gait speed differed depending on the initial gait speed in all studies (e.g., for InCHIANTI, comparing risk differences for a change of 0 m/s and a decrease of 0.1 m/s at starting speeds of 0.6 m/s and 1.0 m/s resulted in an interaction contrast on the additive scale of 11.9% (95% CI57.8-16.9%). No significant sex effects (main effects or interactions) were found. Figure 2B ). No significant time interval effects or interaction terms were found in LIFE-P/LIFE, whereas for BHS2, an alternative model containing significant interaction terms was identified ( Table 2 footnote), with minimal improvement in the AUC when these interactions were added. No significant main effects or interaction terms were found for sex in the models for SR-MD recovery, and for selected speeds, there was no evidence of interaction on an additive scale (Supplemental Table S4 ).
DISCUSSION
We have shown that the relationship between absolute levels of gait speed and SR-MD is context specific and that heterogeneity of important cutpoints can exist across populations. In addition, clinical interpretations of change in usual-pace gait speed relative to transitions in SR-MD across diverse clinical populations vary as a function of initial gait speed. Changes in gait speed of 0.04 to 0.06 m/ s that have been identified 9, 10 as clinically important may not always be associated with clinically important changes in SR-MD.
Gait speed measured over a short distance is a powerful predictor of mobility disability and risk for future events. [1] [2] [3] [4] [5] [6] It has been demonstrated that baseline gait speed over an 8-foot course is almost as good a predictor of 1-and 4-year incident SR-MD 1 as total Short Physical Performance Battery score. 23 It has been reported that a gait speed slower than 1.0 m/s over a 6-m course in wellfunctioning older adults identified people at high risk of future lower extremity limitation. 24 Our findings reinforce the idea that gait speed is an important vital sign in managing the health of older adults.
We highlight 2 clinically relevant points. First, in a older adult without an acute health event, if gait speed is 1.0 m/s or faster, clinicians can be fairly confident that the older adult will not have SR-MD or be at high risk for transitioning to SR-MD within 6 months. Second, for relatively healthy older adults (InCHIANTI) or those with compromised function (LIFE-P/LIFE) who have not experienced a recent serious health event such as hip fracture (BHS2), a gait speed slower than 0.6 m/s probably increases the risk of SR-MD, a cutpoint that is consistent with a recommendation based on previous work. 13 A relatively slow gait speed of 0.31 m/s may be an optimal classification cutpoint in individuals with a recent disability health event, such as hip fracture (BHS2). In the absence of an acute health event such as hip fracture, gait speed may reflect input from multiple domains of physical function, including balance; strength; flexibility; and pulmonary, cardiovascular, and neurological capacities. In effect, it captures a trait-like dimension of physical function. By contrast, acute health events such as hip fracture often represent a state-like condition in which gait speed is dramatically reduced yet has less effect on perception because the condition is viewed as temporary. Although our analyses suggest cutpoints for categorizing SR-MD, the cutpoints should be considered in a relative sense in clinical practice, because people's health and health history will vary. Although estimation of cutpoints within truncated ranges of gait speed will lead to identification of different optimal thresholds within those ranges when considering a single population, we view BHS2, TRAIN, and LIFE as different clinical populations in which health status or events have resulted in truncated gait speed ranges, making estimation of thresholds within these limited ranges reasonable.
Our study is not without limitations. There are differences in how mobility disability was assessed between InCHIANTI and BHS2, on the one hand, and LIFE-P/ LIFE and TRAIN; for this reason, we did not statistically test for consistency of the relationships between studies, nor did we combine data from studies to obtain common estimates. In addition, almost all BHS2 participants used an assistive device after fracture, and a large proportion had long-term functional problems. This acute change in functional status, often characterized by use of an assistive device, has led to including assistive device use in other definitions of mobility disability. 2 We chose a definition that conforms to the literature 17, 18 and represents a form of disability that everyone (patients, families, providers) would agree is significant. For the longitudinal analyses of recovery, none of the ROC values indicated excellent discrimination. 25 Finally, our analyses of transitions attempted to limit the effect of long outlying intervals by excluding small percentages of longer visit intervals caused by missed visits, but the populations in these studies have different intervals of time between visits, further complicating between-study comparisons.
Finally, readers may ask whether it is possible to develop a more "user friendly" approach to evaluating function that would enable clinicians to categorize an individual's risk of an event (e.g., SR-MD) based on his or her functional levels regardless of a specific diagnosis. It is important to emphasize that it is likely that tests of physical function such as gait speed are the final common pathway for multiple problems that arise as people age, including disease presence and severity, sedentariness, psychological impediments, and the aging process itself. As such, these measures can stand on their own as summaries of overall health as people age, are easy to understand, and can be of real value to clinicians. As electronic records improve, it may be possible to use complex analytical methods to develop a functional tool that reduces the need for some level of clinical interpretation. In the interim, the training of geriatricians and other practitioners treating and managing the care of older persons should involve an increased emphasis on gait speed and other dimensions of functional health.
In conclusion, with the goal of providing some guidance to physicians and researchers on how to interpret gait speed in clinical practice, we evaluated the relationship between gait speed and SR-MD in several diverse populations of older adults. The relationship between SR-MD and gait speed in the range of 0.6 to 1.0 m/s appears to be population specific, with values of 0.6 m/s and less being generally associated with reason for concern and values greater than 1.0 m/s having relatively low probabilities of near-future SR-MD. Although single gait speed thresholds may be identified based on different criteria, ranges of gait speeds may be of greatest utility in clinical care. The clinical significance of interpreting change in gait speed on the development of SR-MD depends on initial gait speed and is an area where future study is needed.
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